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ARTICLE
Quantifying Drug-Induced Bone Marrow Toxicity Using a 
Novel Haematopoiesis Systems Pharmacology Model
Chiara Fornari1,*, Lenka Oplustil O’Connor2, Carmen Pin1, Aaron Smith3, James W.T. Yates3, S.Y. Amy Cheung1,6, Duncan I. Jodrell4, 
Jerome T. Mettetal5 and Teresa A. Collins1
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary 
effect is on proliferative progenitors in the bone marrow. Using observations in rat bone marrow and blood, we characterize 
a mathematical model that comprises cell proliferation and differentiation of the full haematopoietic phylogeny, with inter-
acting feedback loops between lineages in homeostasis as well as following carboplatin exposure. We accurately predicted 
the temporal dynamics of several mature cell types related to carboplatin-induced bone marrow toxicity and identified novel 
insights into haematopoiesis. Our model confirms a significant degree of plasticity within bone marrow cells, with the num-
ber and type of both early progenitors and circulating cells affecting cell balance, via feedback mechanisms, through fate 
decisions of the multipotent progenitors. We also demonstrated cross-species translation of our predictions to patients, ap-
plying the same core model structure and considering differences in drug-dependent and physiology-dependent parameters.
Drug-induced myelosuppression is a common dose-limit-
ing adverse event for cancer therapeutics,1 causing delays 
and discontinuation of treatment, which compromise the 
therapy’s success. The cytotoxic activity of antineoplastic 
agents affects highly proliferative bone marrow progeni-
tors, reduces bone marrow cellularity, and disrupts blood 
cell production.2 Carboplatin, which is the standard of care 
treatment for several solid tumors,3 induces DNA damage 
in proliferating bone marrow cells, causing cell death and 
consequent myelosuppression.1 The dose-limiting toxici-
ties in patients receiving carboplatin are thrombocytopenia 
and leukopenia.4,5
Haematopoiesis is an extremely dynamic process that 
comprises highly complex cell differentiation cascades. 
Around 109 red blood cells and 108 white blood cells are 
generated every hour from a common set of haematopoietic 
stem cells (HSCs) in the bone marrow of a healthy adult.6 To 
enhance our understanding of this process, as well as of the 
mechanisms behind drug-induced myelosuppression, it is 
essential to quantify cell dynamics and interactions across 
multiple branches of the haematopoietic phylogeny rather 
than modeling the differentiation of cell lineages in isola-
tion.7 This task is not trivial because the complexity of the 
system’s dynamics arises from the interaction of multiple 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Cancer therapeutics impact on proliferative progeni-
tors in the bone marrow, disrupting the process of hae-
matopoiesis and leading to observed changes in blood 
cell counts. Theoretical models have been used to char-
acterize these variations in peripheral blood cells using 
assumptions based on nonquantified bone marrow 
toxicity.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  This study aims to mechanistically characterize the 
overall carboplatin-induced myelosuppression profile, 
linking carboplatin pharmacokinetics with variations in 
bone marrow progenitors and in circulating blood cells.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Our model describes, quantitatively and mechanisti-
cally, carboplatin-induced DNA damage on bone marrow 
progenitors and how toxicity propagates across cell lin-
eages over time, modifying multiple clinical endpoints in 
peripheral blood.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  Our model captures the complexity and dynamics of 
haematopoiesis and reveals new understanding essential 
for better prediction of drug-induced effects on specific lin-
eages in rat and in man. This approach may be adopted for 
other drugs where myelosuppression is of concern.
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cellular prosurvival mechanisms primed by suppressive 
drug effects.
Clinically, drug-induced myelosuppression is monitored by 
tracking the variation in blood counts,8 which are relatively 
easy to obtain. However, haematological toxicity originates 
in the bone marrow, where proliferative progenitors reside. 
Theoretical models have been used widely to explore hypoth-
eses on nonquantified drug-induced toxicity in the bone mar-
row,7,9 and empirical adjustments are sometimes required to 
capture drug effects over multiple cycles.7,10–12 In a recent re-
view,7 we discussed the possibility of enhancing clinical data 
with complementary information from preclinical studies, 
where measurements in the bone marrow are more feasible.
Here we present a novel quantitative systems pharmacol-
ogy model to describe the link between carboplatin phar-
macokinetic (PK) profiles and variations in bone marrow 
progenitors and in multiple lineages of mature blood cells 
(Figure  1). Combining this theoretical framework with ex-
perimental results in rats, we investigate hypotheses on pro-
genitor cell fate, feedback mechanisms, and the disruption 
of cell dynamics in the haematopoiesis cascade disrupted 
by carboplatin. Furthermore, we translate our preclinical 
findings and predictions to patients by scaling the essential 
features of the haematopoietic process and adjusting the 
drug potency for interspecies variations7,13 (Figure 2).
METHODS
In vivo rat studies
All animal care and experimental procedures used at the 
AstraZeneca facility in the United Kingdom were performed 
under the authority of a valid Home Office Project License 
and they were conformed to the UK Animals (scientific pro-
cedures) Act, 1986. Animal studies are reported in compli-
ance with the ARRIVE (Animal Research: Reporting of In 
Vivo Experiments) guidelines.14,15 
A total of 178 animals were used in these experiments. 
Details of the study design, haematology analysis, flow cy-
tometry analysis, and bioanalysis are reported in Table S1 
and Supplementary Text S1–S4, respectively.
Theoretical description of carboplatin-induced 
myelosuppression
Details on carboplatin pharmacokinetic model are reported 
in Supplementary Text S5.
Figure 1 Carboplatin toxicity in the bone marrow is mechanistically linked with effects in the blood. The diagram provides a graphical 
representation of our quantitative systems pharmacology  model defined in Eqs. 1–9. The formation of every mature blood cell is 
pictured as a path through the haematopoiesis differentiation tree, with haematopoietic stem cells at its top. Haematopoietic stem 
cells mature into MPPs, which then commit to specific lineages giving rise to fully differentiated blood cells. Red triangles highlight 
populations affected by carboplatin. Rat and human symbols mark model variables for which observations in rat and human were 
available. Cell surface markers used to quantify bone marrow progenitors in rats are also reported in the diagram. Proliferative cells are 
affected by carboplatin. Proliferation and maturation in the bone marrow are regulated by the interplay of feedback mechanisms from 
different circulating cells (dotted arrows). CD90+/Lin-, CD90 positive and lineage negative cells; CMP, common-myeloid progenitor; 
MEP, megakaryocyte–erythrocyte progenitor; Mono, monocytes; Neut, neutrophils; MPP, multipotent progenitor; Plt, platelets; RBCs, 
red blood cells; Ret, reticulocytes; T1, T2, T3, transit-compartments.
Bone Marrow Blood
MPPs
CD90+/Lin-
MEPs
CD71+
T1 Ret T2 Ret T3 Ret RBCsReticulocytes
T1 Plt T2 Plt T3 Plt Platelets
CMPs
CD45+
T1 Neut T2 Neut T3 Neut Neutrophils
T1 Mono T2 Mono T3 Mono Monocytes
Data available in rats Data available in patients Drug effects
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We described haematopoiesis as a set of compartments 
connected in branches (one for each lineage), which originate 
from common sources of HSCs and multipotent progenitors 
(MPPs; Figure 1). Branches represent distinct cell lineages 
(neutrophils, monocytes, platelets, erythrocytes), and form 
our model subunits. Note that we did not consider the lym-
phoid branch because the proliferation, activation, and reg-
ulation of lymphoid cells occur mostly in lymphoid organs.16 
Within lineages, compartments correspond to specific hae-
matopoietic cell stages (progenitors, transit cells, mature 
cells), and model variables describe the cell count in each 
of these compartments.17 Our model describes a dynamic 
system of cells continuously proliferating and differentiating, 
able to maintain and recover homoeostasis after perturba-
tions by balanced cell flows across the connected compart-
ments (predecessor–successor populations). The value of 
these flows is determined from the lifespan of cells reported 
in the literature and observed size of compartments.
We described haematopoietic cell dynamics with a system 
of ordinary differential equations, which are here grouped to-
gether by the stage of the haematopoietic cell population 
under analysis (namely, progenitors, transamplifying cells, 
and mature cells).
Progenitor equations. We assumed that all haematopoietic 
cells come from a common pool of MPPs (CD90+/Lineage– 
cells): 
A source of HSCs6 (kstem), whose flow is mediated by a 
feedback function (fdbkstem), feeds into the MPP compart-
ment, and MPPs also increase their number via proliferation 
(k
prolMPP
). MPPs differentiate into the more mature common 
myeloid progenitors (CMPs; CD45+ cells) and megakaryo-
cyte–erythrocyte progenitors (MEPs; CD71+ cells), with 
the rates ktrCMP ,ktrMEP, respectively. MPPs are affected by 
carboplatin, whose effect is described by the parameter 
SlopeMPP. We assumed that the drug effects were driven by 
the cell damage (Damage) and that drug-induced damage 
affected the proliferative fraction of the cell compartment, 
which is denoted by the product of the proliferation rate 
(kprol) and the compartment size (MPP):
We quantified cell damage as the result of (i) the process 
of adducts formation, or DNA Damage, with rate kdam pro-
portional to the concentration of free platinum in plasma, 
and (ii) the DNA repair process, with first-order kinetics (krep), 
as follows:
The CMP and MEP compartments follow similar rules to 
those previously described for MPP:
They proliferate with rates kprolCMP , kprolMEP, respectively, and 
differentiate into the successors of their lineage, i.e., tran-
sit-neutrophils (with rate ktrNeut ) and transit monocytes (with 
rate k
trMono
) for CMP and transit reticulocytes (with rate ktrRet ) 
and transit platelets (with rate ktrPlt ) for MEP. Differentiation 
rates (ktr) were derived resolving the steady-state equations 
reported in Supplementary Text S6 and S7. Similar to MPP, 
CMP and MEP are affected by the cytotoxic activity of car-
boplatin (SlopeCMP, SlopeMEP).
(1)
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MPP
Damage
)
MPP
−k
trCMP
fdbk
matMPP
−k
trMEP
fdbk
matMPP
.
(2)
DrugEffects=Slope×Damage×kprol×Cells.
(3)dDamage
dt
=kdamCpfreePlatinum
−krepDamage.
(4)
dCMP
dt
= k
prolCMP
(
1−Slope
CMP
Damage
)
CMP
+k
trCMP
fdbk
matCMP
MPP−k
trNeut
CMP−k
trMono
CMP,
dCMP
dt
= k
prolMEP
(
1−Slope
MEP
Damage
)
MEP
+k
trMEP
fdbk
matMEP
MPP−k
trRet
MEP−k
trPlt
MEP.
Figure 2 Graphical representation of our theoretical approach developed to investigate drug-induced haematological toxicities. The 
first step consisted of defining a novel global and quantitative system pharmacology model able to integrate data from different sources 
(i.e., rat carboplatin PK, bone marrow effects, and peripheral blood counts) and describe carboplatin-induced myelosuppression 
profiles in rats. Then, we considered the cross-species differences between rat and human to update model parameter values. Last, 
we generated clinical predictions. In addition, when clinical data are available, back-translation can also be performed (dotted gray 
arrow). BM, bone marrow; PK, pharmacokinetic.
Translation
PK, drug sensitivity,
system properties
(turnover rates, ...)
Cross species
differences
Back translation to validate the preclinical model
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Transit compartment equations. We used a chain of 
three non proliferative transit compartments to describe 
maturation of both neutrophils (T1Neut, T2Neut, T3Neut) and 
monocytes (T1Mono, T2Mono, T3Mono):
As previously reported,18 we introduced a new parameter (a) 
to describe maturation rate within each lineage-specific transit 
compartment. We defined this rate as the ratio between the 
number of transit compartments and the maturation time:18
For reticulocytes and platelets, we used a chain of two 
proliferative transit compartments (T1Ret, T2Ret, T1Plt, T2Plt) 
or late progenitor cell populations, thus susceptible to car-
boplatin activity, followed by non proliferative transit com-
partments (T3Ret, T3Plt):
As previously described for neutrophil and monocyte 
maturation, the MTTs of reticulocytes and platelets were de-
fined as:
Lifespans of transit compartments (1/a) and progenitor 
cells (1/ktr) were obtained from the steady-state equations 
(Supplementary Text S6 and S7) and by fitting the model to 
the data (Supplementary Text S8).
The cells in the proliferative transit compartment are af-
fected by the cytotoxic activity of carboplatin with rates 
(δRetSlopeMEP, δPltSlopeMEP), which are proportional to the 
damage induced by carboplatin (Damage) and the prolifera-
tive fraction of the compartment.
Circulating cell equations. After maturation, fully 
differentiated cells are released into the blood:
Circulating rates (kcirc) were derived from cell lifespan val-
ues (1/kcirc) in the literature.
All modeling and simulations were performed in Matlab 
(Mathworks, Natick, MA) toolbox Simbiology (constrained 
nonlinear least-square optimization) and Phoenix non 
linear mixed effect (NLME) 7.0 (Certara, Princeton, NJ; 
Supplementary Text S8 and Supplementary Model Code). 
Identification of values for the model parameters
The lifespans of mature blood cells were derived from rat 
values found in the literature.5,13,17,19 The size of all com-
partments, lifespan and proliferation of transit compart-
ments, and progenitor cells were calculated by solving 
the steady-state equations of the untreated bone marrow 
(Supplementary Text S6 and S7) and by fitting the model 
to our experimental data sets (Supplementary Text S8). 
The parameters describing feedback strength and drug 
effects were calculated by fitting the model to our experi-
mental data sets (Supplementary Text S8). Stability anal-
ysis was also performed with Oscill8 Dynamical Systems 
Toolset (Copyright (C) 2005, Emery Conrad, http://oscil 
l8.sourc eforge.net/), Supplementary Text S8, to identify 
parameter regions leading to oscillatory solutions, which do 
not describe a physiological response of haematopoiesis to 
carboplatin treatment. 
Model translation to the clinic
The parameters of our model were scaled to reflect the dif-
ferences between rat and human (i) haematopoiesis physi-
ology and (ii) carboplatin bone marrow toxicity.
1. The lifespan and the counts of peripheral blood 
cells were obtained from the literature, whereas for 
MPP counts we applied allometric scaling from rat 
to human20 given the specific marker-dependency of 
flow cytometry data. Then we derived CMP and MEP 
counts using the proportions between these popu-
lations and MPP, which are experimentally reported 
(5)
dT1Neut
dt
= ktrNeut
CMP−aNeutT1Neut,
dT2Neut
dt
= aNeutT1Neut−aNeutT2Neut,
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dt
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for humans21 (Supplementary Text S9). Mean transit 
times in humans were calculated from the literature5 
according to the number of non proliferative transit 
compartments in our model.
2. The drug-dependent parameters, denoted Slope, were 
scaled using species-specific in vitro drug potency 
experimental results (Table S2 and Supplementary 
Text S10), which express the drug effect on several 
proliferative cell types. To scale these parameters, we 
used a previously reported expression13 with the fol-
lowing form:
where correcting for the cross-species differences in the 
fraction of unbound drug was not needed for carboplatin.
Last, the human carboplatin PK was simulated using a 
previously reported model22 (Supplementary Text S11).
RESULTS
A new quantitative systems pharmacology model for 
haematopoiesis
Our novel approach describes cell dynamics in the haema-
topoietic system based on the proliferation, differentiation, 
and interaction of feedback processes across some of the 
major branches of the haematopoietic phylogeny.23 This 
theoretical framework was able to quantify the temporal dy-
namics of carboplatin-induced DNA damage on progenitor 
cells in the bone marrow, which is the drug site of action, 
together with the downstream impact of this bone marrow 
toxicity on mature blood cells.
The final model structure contains the formation of dis-
tinct blood cell lineages as branches of transit compart-
ments originated from a common source of early progenitors 
(Figure 1). Each branch incorporates the dynamics of cell 
proliferation, lineage differentiation, and negative feedback 
processes in response to stimuli.7 These feedback loops 
connect cells across lineages and regulate the proliferation 
and differentiation of common progenitors to rescue the 
depleted populations.24 This results in a haematopoietic 
dynamic system in homeostatic equilibrium capable to re-
cover25,26 after perturbations (Figures 3, S1, S2). Parameter 
values are reported in Tables 1, 2, S3, and S4.
Carboplatin-induced DNA damage drives proliferative 
cell loss
We observed that nucleated cells in the bone marrow 
started to decrease from the first administration of carbo-
platin. The nadir was observed 3–4 days post dosing, when 
free platinum, which is the active species of carboplatin 
and that is cleared relatively rapidly from blood27,28 (Figure 
S3), was not detected in either blood or bone marrow (data 
not shown). Seven days from dosing, although the recovery 
process had started, the bone marrow cells were still com-
promised (Figures 3 and S1).
Similar to previous reports,29 we accounted for this ob-
served temporal disconnection between free platinum 
concentration and effects on haematopoietic cells, model-
ing carboplatin toxicity as a function of the DNA damage 
(10)SlopeH,IC50=SlopeR×
(
IC50H
IC50R
)−1
,
Figure 3 Overall myelosuppression profile induced by repeated cycles of carboplatin 40 mg/kg. Rats were dosed with carboplatin 
40 mg/kg on day 1 of repeated 14-day cycles (Table S1). Plots show the time course of carboplatin effects across the main bone 
marrow progenitor populations (multipotent progenitors, common-myeloid progenitors, megakaryocyte–erythrocyte progenitors) 
and mature blood cells (neutrophils, monocytes, platelets, reticulocytes, red blood cells). Multipotent progenitor, common-myeloid 
progenitor, megakaryocyte–erythrocyte progenitor, neutrophil, monocyte, and red blood cell total counts go down over multiple 
cycles, whereas reticulocyte and platelet recovery to baseline (after rebound) is still possible. Points show the observations, red 
lines show average model predictions, and blue shadow areas show percentiles in the simulated data. Visual predictive checks were 
generated from 1,000 simulations using the log-additive residual errors reported in Table S4. d, days.
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Table 1 Physiology-dependent system parameters
Description Parameter Unit
Rat Human
Value CV (%) Source Value Source
Circulating rates
Neutrophil circulating rate kcircNeut 1/hour 0.17 –
45 0.1 22
Monocyte circulating rate kcircMono 1/hour 0.06 –
45 0.04 41
Platelet circulating rate kcircPlt 1/hour 0.01 –
46 0.0052 5
Red blood cell circulating rate kcircRBC 1/hour 0.0007 –
45 0.00037 13
Baseline values
Neutrophil baseline value Neut0 10
9 cells/L 1.32 2.6 Estimated 2–7 22
Monocyte baseline value Mono0 10
9 cells/L 0.16 2.6 Estimated 0.2–10 41
Platelet baseline value Plt0 10
9 cells/L 967 2.5 Estimated 345 5
Reticulocyte baseline value Ret0 10
9 cells/L 235 2.7 Estimated 40–115 1
Red blood cell baseline value RBC0 10
9 cells/L 8,161 2.2 Estimated 4,100–5,900 32
Multipotent progenitor baseline value MPP0 10
9 cells/L 69 4.6 Estimated 1.3 Allometric scaling ref. 42
Common myeloid progenitor baseline value CMP0 10
9 cells/L 214 4.1 Estimated 20.9 Proportions from ref. 43
Megakaryocyte–erythrocyte progenitor 
baseline value
MEP0 10
9 cells/L 156 5.2 Estimated 15 Proportions from43
Transient times
Neutrophil mean transient time MTTNeut hour 61.5 56 Estimated 210 Scaled from ref. 
5
Monocyte mean transient time MTTMono hour 62.2 55 Estimated 121.5 Scaled from
47
Platelet mean transient time MTTPlt h 74 5.6 Estimated 168 Scaled from
5
Reticulocyte mean transient time MTTRet hour 75 4.8 Estimated 66 Scaled from internal AZ 
study (data not shown)
Steady-state equation parameters
Reticulocyte 1st transit compartment 
baseline value
λ1 Dimensionless 2 – Fixed 2 As in the rat
Platelet 1st transit compartment baseline 
value
λ2 Dimensionless 2 – Fixed 2 As in the rat
Proliferation rate CMPs λ3 Dimensionless 1.8 – Fixed 1.8 As in the rat
Proliferation rate MEPs λ4 Dimensionless 1.8 – Fixed 1.8 As in the rat
Proliferation rate MPPs λ5 Dimensionless 1.8 – Fixed 1.8 As in the rat
Feedback powers controlling
MPP zero order proliferation rate γstem Dimensionless 0.07 – Fixed 0.07 As in the rat
MPP maturation rate toward CMPs γMatCMP Dimensionless 0.6 – Fixed 0.6 As in the rat
MPP maturation rate toward MEPs γMatMEP Dimensionless 0.3 – Fixed 0.3 As in the rat
First-order proliferation rates of  
T1Ret, T2Ret, T1Plt, T1Plt
γ
prolTrans
Dimensionless 0.7 – Fixed 0.7 As in the rat
Damage
Damage creation kdam 1/hour 0.017 – Fixed 0.017 As in the rat
Damage repair krep 1/hour 0.017 – Fixed 0.017 As in the rat
Values for rat were obtained from the literature, when available; estimated by fitting the model to the data; or derived/fixed from experiments. Human values 
were derived from literature or scaled as explained in the main text and in the Supplementary Material. Coefficient of variation (CV%) values show the 
confidence in our parameter estimates. AZ, AstraZeneca; T1, T2, proliferative transit-compartments.
Table 2 Drug-dependent system parameters
Description Parameter
Rat Human
Unit Value CV (%) IC50 scaled value
Carboplatin effects in multipotent progenitors SlopeMPP 1/μM 2.05 11.8 0.79
Carboplatin effects in common myeloid progenitors SlopeCMP 1/μM 1.47 8.6 0.57
Carboplatin effects in megakaryocyte–erythrocyte progenitors SlopeMEP 1/μM 2.19 10.3 0.66
Carboplatin effects in reticulocyte proliferating transit-compartments δRet Dimensionless 2.8 21 2.8 (as in rat)
Carboplatin effects in platelet proliferating transit compartments δPlt Dimensionless 0.54 30.4 0.54 (as in rat)
Carboplatin effects in rat were estimated by fitting the model to the data. Human values were calculated by adjusting the rat values for species-specific drug 
sensitivity 
(
Slope
H,IC50
=Slope
R
×
IC50H
IC50R
)−1
, Eq. 10. The IC50 values used to scale drug effects are reported in Table S3. Coefficient of variation (CV%) values 
show the confidence in our parameter estimates. IC50, half maximal inhibitory concentration.
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(Damage) caused by the formation of platinum DNA ad-
ducts, which persist in the system longer than free plati-
num28–30 (Eq. 3; Figure S3).
Drug effects in Eqs. 1, 4, and 7 are driven by the dam-
age-induced cell death, which occurs in the proliferative 
fraction of the cell population compartment (Eq. 2). Notice 
that the cell death rate (Slope) is independent of both the 
time and the structural scale of the system, and it is ready 
to be used for the extrapolation of predictions across 
scales and species with the same sensitivity to carboplatin. 
Moreover, Eq. 2 describes the drug effect as independent of 
any feedback mechanism activated by perturbations, which 
improves the computational tractability of our model when 
compared with previous approaches.17,31
Under these assumptions, our model explained the lack 
of synchronicity between free platinum plasma kinetics 
(Figures 3 and S1) and the depletion of bone marrow popu-
lations previously described.
MPPs are rescued during injury
Similar to previously published models,32,33 we imple-
mented a flow of cells, or source of HSCs (Source), feeding 
into the MPP compartment (Eq. 1). In our model, the value of 
this flow is regulated by negative feedback signals (fdbkstem 
in Eq. 1) coming from the MPP descendants CMPs and/or 
MEPs, which is supported by experimental evidence.24 A 
decrease of the descendants below their homeostatic val-
ues (CMP0, MEP0) increases the flow of cells into the MPPs 
compartment. This was modeled by including the following 
feedback factor into Eq. 1:
which enabled to upregulate MPP levels after carboplatin 
exposure and hence model the observed oscillations of 
CMP and MEP in response to carboplatin (Figures 3, S1). 
Because of the rather small value of γ stem when compared 
with the other feedback values, the effect of fdbkstem func-
tion on MPP dynamics were quite mild (i.e., kstem rate in-
creased 27% when the feedback was at its maximum). 
However, this was enough to counterbalance MPP cell 
loss as a result of their differentiation into CMP and MEP,24 
which are also regulated by feedback functions (Eq. 12).
CMPs fail to balance carboplatin-induced cell loss
We observed a mild depletion of CD45+ cells (CMP); how-
ever, the recovery of this population was relatively slow, and 
homeostasis was not restored before the start of the next 
14-day cycle, leading to a progressive reduction of CMP 
population from the first carboplatin dose (Figures 3 and 
S4). This was explained assuming that CMP proliferation rate 
together with feedback mechanisms controlling the in-flow 
of cells into CMP compartment were not able to rebalance 
the cell loss induced by carboplatin. Consequently, white 
blood cell counts decreased progressively during the ad-
ministration schedule (Figures 3 and S4), and we estimated 
a recovery period of ~50 days to reinstate at least 80% of 
the original CMP population after the last carboplatin cycle.
Circulating cells regulate MPP cell fate
Analysis of the progenitors in the bone marrow revealed 
that the most affected populations were CD90+/Lin- cells 
and CD71+ cells, i.e., MPPs and MEPs, respectively. 
In the first 3 dosing cycles, both MPP and MEP expe-
rienced great cell loss followed by a recovery process 
that, because of the well-established negative feedback 
loops,34,35 led to values first exceeding and then con-
verging to baseline before the following cycle started 
(Figure 3). In our experiments, where bone marrow sta-
tus was not assessed again until the eighth cycle, full re-
covery was not achieved (Figure S4). We assumed that 
this resulted from the interaction of different cellular pro-
survival mechanisms that regulate bone marrow cell dy-
namics,25 and we defined not only proliferation but also 
maturation25,36 as dependent on the level of circulating 
cells through feedback loops. We modeled the cell flows 
from MPP into CMP and MEP as dependent on feedback 
signals originated from circulating cells with the following 
functions
which are integrated in Eqs. 1 and 4. These functions define 
cross-lineage effects and most likely describe the impact of 
signals mediated by lineage-specific cytokines,7,37 such as 
erythropoietin for erythrocytes, granulocyte colony stimu-
lating factor for neutrophils, and macrophage colony stim-
ulating factor for monocytes, on MPP cell-fate decision.38 
This is a vital process enabling the rapid recovery follow-
ing myelosuppression; however, we do not have experi-
mental measurements of such cytokines in this particular 
study, and as a result we have taken an empirical approach 
based on deviations of mature circulating cell counts from 
baseline values. Differentiation of MPP into CMP is fa-
vored by reduced white blood cell counts39 or equivalently 
by increased granulocyte and monocyte stimulating fac-
tors, whereas maturation toward MEP is controlled by red 
blood cells29 or erythropoietin. The effects of these feed-
back functions can be quantified from the recovery times 
required by each progenitor cell population after the last 
carboplatin cycle. We estimated that MEP require 12 days 
to reinstate at least 80% of their original population size vs. 
the 30 days required by MPP.
Figure  3 shows that, when considering feedback from 
circulating cells on MPP maturation, as described in Eq. 12, 
the model predicted the observed decreasing numbers of 
progenitors in successive cycles, whereas this pattern was 
not predicted when feedback mechanisms were modulating 
only proliferation (Figure S5). This hypothesis is supported 
by independent experimental findings, which suggest that 
high levels of erythropoietin, in response to the progressive 
depletion of red blood cells, introduces bias in the differ-
entiation process, guiding MPP fate in favor of committed 
erythroid progenitors.40
(11)fdbkstem=
(
1
2
CMP0
CMP
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1
2
MEP0
MEP
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,
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,
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,
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Reticulocyte and platelet transit cells proliferate
Carboplatin induced severe depletion in reticulocytes 
and platelets, for which the nadir was more than 95% and 
45% reduction from baseline, respectively. However, as 
previously reported,29,41 within each one of the eight cy-
cles, we observed a strong rebound of these populations 
exceeding by 290% and 180% their baseline, respec-
tively, before the recovery of homeostatic values. These 
large oscillations could not be explained by toxicity and 
proliferation of their common progenitor, MEP (Figure 
S6). We hypothesized that the first two transit compart-
ments of reticulocytes35 and platelets42 are proliferative 
and thus also sensitive to carboplatin. Furthermore, we 
also considered that erythropoietin and thrombopoietin 
significantly affected proliferation in these erythroid and 
platelet transit-amplifying compartments by a negative 
feedback loop from circulating cells expressed by the fol-
lowing functions
which are included in Eq. 7.
Under the hypothesis that immature transit cells are pro-
liferative (i.e., late progenitor cells), the large oscillations 
observed in circulating reticulocytes and platelets were ac-
curately described by the model (Figure  3). Using stability 
analysis, we found that the power of the feedback function 
defined in Eq. 13 (γprolTrans) is a crucial parameter that can lead 
our system into oscillatory solutions and that does not de-
scribe a physiological haematopoiesis process (Figure S7).
Clinical predictions
We assumed that parameter values, but not model 
structure (i.e., haematopoiesis biology), were species 
dependent. Model predictions generated scaling our 
mathematical model (Eqs.  1–9) to reflect the differences 
between rat and human haematopoiesis physiology (e.g., 
population size, maturation time, etc.), but using the 
drug-effect parameters estimated in rats did not reflect 
accurately either clinical neutropenia or thrombocytopenia 
(Figure 4). Therefore, we scaled our mathematical model 
to also account for the differences in sensitivity to carbo-
platin between human and rat bone marrow cells. Then, 
we provided predictions in patients and compared these 
with simulated clinical data, which were generated using 
the model by Schmitt et al.5 (Supplementary Text S12).
Our in vitro experimental results suggested that carbo-
platin is more potent in rat than human, with MEP being 
more sensitive than CMP in both species (Table S2). After 
scaling the drug-effect parameters according to the ob-
served species-specific drug sensitivity (Eq.  10), both 
clinical neutropenia and thrombocytopenia predictions im-
proved (Figure 4). Precisely, the percentages of patients 
experiencing grade 3 and grade 4 neutropenia and grade 
3 thrombocytopenia were predicted within onefold differ-
ence (Figure  4c). However, grade 4 thrombocytopenia 
remained underpredicted by fourfold, suggesting that fur-
ther understanding of the differences between human and 
rat platelet biology is crucial for increasing confidence in 
the predictions of severe clinical thrombocytopenia. Other 
factors that could affect the predictions are the underly-
ing disease itself or impaired bone marrow function as a 
result of previous treatments, which would also impact on 
haematopoietic recovery, and these features were not ac-
counted in our translation.
DISCUSSION
In this study, we described a new systems pharmacology 
model of haematopoiesis that quantitatively and mechanis-
tically links carboplatin-induced effects in the bone mar-
row with multiple clinical endpoints, considering various 
lineages of the haematopoietic phylogeny, cellular turn-
over, and interaction among lineage-dependent feedback 
loops (Figure  1) rather than effects on single lineages in 
isolation.7 We used the rat as a model system to investigate 
haematotoxicity, and we accurately predicted the temporal 
dynamics of bone marrow progenitors and mature blood 
cells with our theoretical model.
Carboplatin-induced loss of proliferative cells is driven by 
DNA damage, which is caused by the formation of platinum 
DNA adducts,28,30 and these adducts are stable for days28,30 
after carboplatin is cleared. We modeled the temporal dy-
namics of the damage induced by platinum DNA adducts 
(Eqs. 2, 3) in proliferative progenitors, and this was sufficient 
to capture the observed lack of synchronicity between car-
boplatin plasma kinetics and the response of bone marrow 
populations (Figures 3 and S3).
When homeostasis is perturbed, the number and type 
of progenitor cells in the bone marrow, as well as of circu-
lating cells, influence the balance between cell in flow and 
out flow in early progenitor populations via complex in-
teracting feedback signals to facilitate the recovery of the 
system. In our model, the feedback signals affect not only 
the proliferation potential of susceptible populations but 
also impact cell-fate decision at a higher level by modulat-
ing the competitive equilibrium between pro-proliferation 
and pro-differentiation inputs coming from other progen-
itors and mature cells. For instance, we observed that 
MPP progenitors lost their capacity to recover baseline 
values after successive dosing cycles (Figure S4). To ex-
plain this result, and in agreement with previously reported 
findings,40 we hypothesized that, after several cycles of 
carboplatin, erythropoietin levels raised to rescue the pro-
gressive (but late) detectable loss of red blood cells, thus 
inducing bias toward erythroid lineages.40 This is achieved 
by disrupting the equilibrium controlling cell-fate decision 
and favoring MPP differentiation into the erythroid lineage 
over proliferation (Figure  3). These model assumptions 
reflect a degree of plasticity of haematopoietic progeni-
tors to rapidly respond to strong perturbations.43 In this 
respect, a number of studies suggest that, in some patho-
logical conditions, HSCs are even able to shift out of the 
haematopoietic hierarchy and transdifferentiate into cell 
types that belong to other organ systems, although these 
results remain controversial.44
(13)
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Furthermore, we observed large oscillations in reticu-
locyte and platelet counts, which MEP proliferation activ-
ity coupled with carboplatin cytotoxicity were not able to 
capture (Figure S6). We described these large variations 
(Figure  3) by assuming that T1Ret, T2Ret, T1Plt, T2Plt are 
proliferative compartments (i.e., late progenitor popula-
tions) and thus are susceptible to carboplatin toxicity, and 
with a proliferation potential responsive to erythropoie-
tin-mediated35 and thrombopoietin-mediated42feedback, 
respectively.
Beyond this exemplar case with carboplatin, our ap-
proach easily enables the incorporation of additional mo-
tifs capturing cell type–dependent and drug-dependent 
mechanisms that act at the molecular scale and drive the 
haematopoietic response. For instance, modeling how 
specific progenitor cell types cope with DNA damage45 
will enable the quantification of the haematological toxic-
ity of DNA damage repair inhibitors. Similarly, the effects 
of cytokines, such as granulocyte-colony stimulating fac-
tor on progenitors’ proliferation and differentiation46 can 
be measured and then explicitly considered to predict the 
rescuing effects of adjuvant therapies during chemother-
apy.39 For this purpose, hypotheses derived from in vitro 
systems, such as bone marrow organ-on-a-chip, where 
a niche of HSCs and progenitors sustains a dynamic 
haematopoietic system,47 could be integrated into the 
model to quantify cytokine-driven feedback dynamics.7 
Other aspects are the investigations of bone marrow mi-
croenvironments or niches6 and the spatial properties of 
the haematopoietic system. Our model hypotheses can 
be integrated in computational models48 and/or partial 
differential equations that, combined with high-resolution 
imaging techniques, will enable the study of the effect of 
the microenvironment or niche6 on HSCs and early pro-
genitors cell-fate decision.49
We demonstrated the application of our model to de-
scribe carboplatin toxicity and, based on the assumption 
that the same core structure would apply to human (i.e., 
assuming a conserved haematopoiesis biology across spe-
cies), we showed the translation of our theoretical insights 
and predictions for the observed clinical neutropenia and 
grade 3 thrombocytopenia induced by carboplatin treatment 
(Figure  4). We accounted for known cross-species differ-
ences in model parameters, tested hypotheses about expo-
sure–response relationships, and made assumptions where 
knowledge was not available (e.g., allometric scaling of pa-
rameters).50 Although extrapolation beyond the observed 
data must always be undertaken with caution, our multi-
disciplinary approach can be easily adapted to model the 
impact of other drugs on patients’ bone marrow, where the 
Figure 4. Clinical predictions of carboplatin-induced neutropenia and thrombocytopenia were generated translating our quantitative 
systems pharmacology model of carboplatin-induced myelotoxicity from rat to human. Clinical predictions (solid red lines) generated 
using the same slope values as those estimated from the rat (a) and predictions generated using slope values adjusted for species-
specific drug sensitivity, Eq. 10, Table 2 (b), were compared with clinical data of carboplatin-induced neutropenia and thrombocytopenia 
described in ref.5 which are represented by solid (means) and dotted (percentiles) blue lines. Blue shadow areas show percentiles in 
our simulations (1,000 individuals), dotted horizontal black lines are thresholds for grades 3 and 4 (neutropenia and thrombocytopenia). 
Two cycles of 21 days of carboplatin were simulated. Doses were calculated with the Calvert formula,51 targeting an AUC(0–24) of 5 (mg/
mL) minutes (Supplementary Text S11). The predicted percentages of patients with neutropenia (top) and thrombocytopenia (bottom) 
grades with those in ref.5 are compared (c). d, days. AUC(0-24), area under the curve in the 24 h time interval; IC50, half maximal 
inhibitory concentration.
(b)(a) (c)
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sampling of such cells is rarely feasible. Likewise, bone mar-
row disease models, such as for acute myeloid leukemia,31 
can be straightforwardly built on our theoretical framework 
to provide prospective clinical predictions for different pa-
tient populations.
Altogether, our quantitative systems toxicology approach 
enables the investigation of the effects of compounds and 
combinations, with substantial potential to explore new 
schedules and inform drug-induced effects in man, prior to 
the initiation of clinical trials.
Supporting Information. Supplementary information accompa-
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